El interés en corto de Tharimmune da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Tharimmune. Los datos de interés en corto se actualizan cada dos semanas.

Tharimmune (NASDAQ:THAR) Bolsa, Informe de interés en corto

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

News

Management

UGI Corporation Appoints Julie Fazio As President Of UGI International, Effective Immediately

Guidance

STKS

The ONE Group Sees Q1 Total Revenues $200M-$205M vs $207.475M Est., Sees 2025 Total Revenues $835M-$870M vs $848.112M Est.

&nbsp;Rocket Lab will launch its next Electron rocket no earlier than March 15th NZDT for its customer iQPS, followed three days later by its latest launch for Kinéis, a global Internet-of-Things (IoT) connectivity provider, during a launch window that opens on March 18th NZDT.&nbsp;

SPACE

General

RKLB

Rocket Lab Schedules Two Launches Three Days Apart

Vail Resorts Sees FY25 Net Income $257M-$309M

Earnings

Earnings Beats

Earnings Misses

The One Group Hospitality Q4 2024 Adj. EPS $(0.03) Misses $0.03 Estimate, Sales $221.880M Beat $217.713M Estimate

CHRS

Coherus Biosciences Projects Post-UDENYCA-Close Cash Of ~$250M And Cash Runway Projections Exceeding Two Years, Past Key Data Readouts Expected In 2026.

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 15 years by 1.39% on an annualized basis producing an average annual return of 12.44%. Currently, Caterpillar has a market capitalization of $166.67 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 15 years ago, it would be worth $580.48 today based on a price of $345.21 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741637709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Caterpillar Stock In The Last 15 Years

Contracts

GETY

Getty Images Signs Multi-Year Agreement With Women's Soccer League; Terms Not Disclosed

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.13) by 115.38 percent. This is a 54.84 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $54.144 million which beat the analyst consensus estimate of $47.270 million by 14.54 percent. This is a 40.84 percent decrease over sales of $91.524 million the same period last year.

Coherus BioSciences Q4 2024 Adj. EPS $(0.28) Misses $(0.13) Estimate, Sales $54.144M Beat $47.270M Estimate

Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) reported quarterly earnings of $6.56 per share which beat the analyst consensus estimate of $6.34 by 3.47 percent. This is a 13.89 percent increase over earnings of $5.76 per share from the same period last year. The company reported quarterly sales of $1.14 billion which met the analyst consensus estimate. This is a 5.48 percent increase over sales of $1.08 billion the same period last year.

Vail Resorts Q2 2025 GAAP EPS $6.56 Beats $6.34 Estimate, Sales $1.14B Inline

<a href="https://www.globenewswire.com/Tracker?data=JaDLNMa0hSPodLHfM8gZ1qinklLnTD4AJDDyo4t4ub4jqDgHs8hOOhD6d_luIBwmeb5FcmMOU5enqEE63NR5I7iYp6GSySbfLVyuCuatVwiKWVNM2XaoyfY62_5ASNhg">Getty Images</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>), a preeminent global visual content creator and marketplace, has been named the Exclusive Commercial Photography and Imagery Licensing Partner of the <a href="https://www.globenewswire.com/Tracker?data=grO-oWgO22qMhqFLFrD2r_HGLLiO-ED49UaRQZMpzESitk5jAQWSGfKDR6dX1aNzZgzNsVhhewTELnVmfBvGsy78_reKAAAHiMftcptdI9A1CVfChxTgieFYloaoeKEe">National Women's Soccer League</a> (NWSL). The NWSL regular season kicks off on March 14, 2025, with all 14 teams taking the pitch across the weekend.
As part of the multi-year agreement, Getty Images' award-winning sports photographers and editors will deliver high-quality imagery from all upcoming matches and events, including the regular season, NWSL Playoffs, NWSL Championship and team media days for all clubs. This includes exclusive access to on and off-the-pitch action, such as gameplay, warmups, fan interactions, celebrations, and more, all to be distributed exclusively through gettyimages.com for both editorial and commercial uses.

Getty Images Signs Multi-Year Photography Partnership As The Exclusive Commercial Photography And Imagery Licensing Partner Of The National Women's Soccer League

OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(0.74) by 85.14 percent.

OKUR

OnKure Therapeutics Q4 2024 GAAP EPS $(1.37) Misses $(0.74) Estimate

Accordingly, the Company is recording a litigation accrual in the Company's fourth quarter 2024 consolidated financial statements of $23.0 million, or $17.1 million after tax. Details on the settlement agreement and the financial impact of the litigation accrual on fourth quarter and full-year 2024 results were included in Current Reports on Form 8-K filed today with the Securities and Exchange Commission. The Company does not anticipate that additional amounts will be accrued for this matter in 2025 or other future periods, and it does not expect any changes to its previously published 2025 guidance as a result of the settlement.

Legal

FISI

Financial Institutions Settles Civil Litigation

Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.42) by 7.14 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.08 million which missed the analyst consensus estimate of $2.11 million by 1.39 percent. This is a 41.62 percent decrease over sales of $3.56 million the same period last year.

CRBU

Caribou Biosciences Q4 2024 GAAP EPS $(0.39) Beats $(0.42) Estimate, Sales $2.08M Miss $2.11M Estimate

Canterbury Park Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPHC#NASDAQ">CPHC</a>) reported quarterly losses of $(0.25) per share. This is a 192.59 percent decrease over earnings of $0.27 per share from the same period last year. The company reported $11.98 million in sales this quarter. This is a 4.39 percent decrease over sales of $12.53 million the same period last year.

CPHC

Canterbury Park Holding Q4 EPS $(0.25) Down From $0.27 YoY, Sales $11.98M Down From $12.53M YoY

ORCL

Oracle Chairman And CTO Larry Ellison Says 'We are on schedule to double our data center capacity this calendar year,'

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. The company reported quarterly sales of $12.10 million which beat the analyst consensus estimate of $9.90 million by 22.25 percent. This is a 154.42 percent increase over sales of $4.76 million the same period last year.

Myomo Q4 2024 Adj EPS $(0.01) Beats $(0.02) Estimate, Sales $12.10M Beat $9.90M Estimate

Editor&#8217;s Note: This article has been updated to improve relevance and clarity.
Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares are down 2.6% to $40.33 in Monday&#8217;s session and have fallen 10% over the past five sessions. The decline comes as U.S. stock futures drop amid <a href="https://www.benzinga.com/general/market-summary/25/03/44216011/us-stocks-likely-to-open-lower-after-trump-hints-at-looming-recession-expert-says-cant-rule-out-a-bear-market-as-indices-inch-towards-correction-territory">growing recession fears</a> and rising trade tensions between the United States and China. 
The financial sector, which has been under pressure from <a href="https://www.benzinga.com/quote/UTEN">rising Treasury yields</a> and investor uncertainty, saw significant losses, with Bank of America among the hardest hit.
What To Know: The selloff comes amid remarks from former President Donald Trump, who on Sunday acknowledged the possibility of a recession in 2024 while maintaining confidence in the long-term economic outlook.
Read Also: <a href="https://www.benzinga.com/news/25/03/44213871/canadas-next-pm-mark-carney-vows-to-win-trade-war-with-trump-says-americans-should-make-no-mistake">Canada&#8217;s Next PM Mark Carney Vows To Win Trade War With Trump: &#8216;Americans Should Make No Mistake&#8217;</a>
Bank of America, one of the largest financial institutions in the U.S., is particularly sensitive to economic fluctuations due to its vast exposure to consumer banking, lending and investment services. 
Rising Treasury yields, with the 10-year yield standing at 4.24% and the two-year yield at 3.94%, put pressure on the bank's fixed-income investments, potentially squeezing profit margins. 
What Else: Additionally, the recent <a href="https://www.benzinga.com/25/03/44189725/unemployment-rate-ticks-higher-in-february-us-economy-adds-fewer-jobs-than-expected">mixed economic data</a>—including a weaker-than-expected jobs report and a surprise rise in the unemployment rate to 4.1%—added to concerns about slowing economic growth and its repercussions for financial institutions.
Compounding the negative sentiment, China's recent decision to impose <a href="https://www.benzinga.com/25/03/44217379/china-hits-soybeans-with-tariffs-its-largest-us-import-along-with-other-agri-products-here-a-list-of-stocks-and-etfs-that-could-be-impacted">retaliatory tariffs</a> on U.S. agricultural goods, including soybeans, added another layer of uncertainty. 
Bank of America, like other major banks, has exposure to global markets and trade activity, and any prolonged trade tensions could further dampen economic growth, impacting corporate borrowing and investment banking revenues.
Investors can gain exposure to&nbsp;BAC by&nbsp;investing&nbsp;in the&nbsp;Financial Select Sector SPDR Fund&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NASDAQ">XLF</a>).
Read Also: <a href="https://www.benzinga.com/25/03/44200382/5-precious-metals-that-could-add-luster-to-your-portfolio-in-2025">5 Precious Metals That Could Add Luster To Your Portfolio in 2025</a>
<h2 class="wp-block-heading">How To Buy BAC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)'s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BAC has a 52-week high of $48.08 and a 52-week low of $34.15.

What's Going On With Bank Of America (BAC) Shares (UPDATED)

Mission Produce Sees Q2 2025 Industry Volumes Consistent With Prior Year Period

HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.12 by 58.33 percent. This is a 71.21 percent decrease over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $234.81 million which missed the analyst consensus estimate of $246.60 million by 4.78 percent. This is a 22.03 percent decrease over sales of $301.15 million the same period last year.

HighPeak Energy Q4 Adj $0.19 Beats $0.12 Estimate, Sales $234.81M Miss $246.60M Estimate

Biotech

Press Releases

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Cover – see more stocks inside…

New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback"

Events

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Offerings

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Comments

Tharimmune

Interés en corto

Tharimmune (NASDAQ:THAR) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL